Lois Brafman

1.6k total citations
22 papers, 1.2k citations indexed

About

Lois Brafman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Lois Brafman has authored 22 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Lois Brafman's work include Cancer Treatment and Pharmacology (10 papers), Bone health and treatments (5 papers) and Cancer-related cognitive impairment studies (4 papers). Lois Brafman is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Bone health and treatments (5 papers) and Cancer-related cognitive impairment studies (4 papers). Lois Brafman collaborates with scholars based in United States, United Kingdom and Canada. Lois Brafman's co-authors include Dawn L. Hershman, Katherine D. Crew, Déborah Fuentes, Heather Greenlee, Jillian L. Capodice, Danielle Awad, Álex de la Sierra, George Raptis, Grace Kranwinkel and Wei Yann Tsai and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and Cancer.

In The Last Decade

Lois Brafman

21 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lois Brafman United States	11	832	308	159	159	125	22	1.2k
Danielle Awad United States	11	829 1.0×	147 0.5×	136 0.9×	196 1.2×	65 0.5×	22	1.2k
Déborah Fuentes United States	6	527 0.6×	259 0.8×	89 0.6×	155 1.0×	97 0.8×	11	836
Peng Sun China	23	484 0.6×	748 2.4×	175 1.1×	52 0.3×	393 3.1×	80	1.8k
Richard J. Kaufman United States	16	553 0.7×	135 0.4×	205 1.3×	52 0.3×	187 1.5×	34	1.1k
Dorothea Fischer Germany	18	323 0.4×	149 0.5×	130 0.8×	31 0.2×	152 1.2×	71	1.2k
Sylvie Mesrine France	26	638 0.8×	607 2.0×	116 0.7×	7 0.0×	160 1.3×	55	1.8k
John C. Michalak United States	19	1.0k 1.2×	251 0.8×	367 2.3×	73 0.5×	145 1.2×	24	1.9k
P Rissanen Finland	17	364 0.4×	121 0.4×	141 0.9×	20 0.1×	207 1.7×	60	965
Antonio Bianco Italy	17	269 0.3×	108 0.4×	120 0.8×	35 0.2×	135 1.1×	37	864
Karineh Tarpinian United States	7	277 0.3×	172 0.6×	112 0.7×	107 0.7×	124 1.0×	8	552

Countries citing papers authored by Lois Brafman

Since Specialization

Citations

This map shows the geographic impact of Lois Brafman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lois Brafman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lois Brafman more than expected).

Fields of papers citing papers by Lois Brafman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lois Brafman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lois Brafman. The network helps show where Lois Brafman may publish in the future.

Co-authorship network of co-authors of Lois Brafman

This figure shows the co-authorship network connecting the top 25 collaborators of Lois Brafman. A scholar is included among the top collaborators of Lois Brafman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lois Brafman. Lois Brafman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Greenlee, Heather, Christine L. Sardo Molmenti, Katherine D. Crew, et al.. (2016). Survivorship care plans and adherence to lifestyle recommendations among breast cancer survivors. Journal of Cancer Survivorship. 10(6). 956–963. 46 indexed citations

Xiao, Tong, Mary Beth Terry, Matthew Maurer, et al.. (2015). Safety, Feasibility, and Biomarker Effects of High-Dose Vitamin D Supplementation Among Women at High Risk for Breast Cancer. PubMed. 2015(Suppl 1). 1–9. 26 indexed citations

Hershman, Dawn L., Heather Greenlee, Danielle Awad, et al.. (2013). Randomized controlled trial of a clinic-based survivorship intervention following adjuvant therapy in breast cancer survivors. Breast Cancer Research and Treatment. 138(3). 795–806. 98 indexed citations

Greenlee, Heather, Katherine D. Crew, Theresa Shao, et al.. (2012). Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer. Supportive Care in Cancer. 21(4). 1077–1087. 37 indexed citations

Awad, Danielle, Kevin Kalinsky, Matthew Maurer, et al.. (2012). Abstract P2-12-01: Prospective Evaluation of Joint Symptoms in Postmenopausal Women Initiating Aromatase Inhibitors for Early Stage Breast Cancer. Cancer Research. 72(24_Supplement). P2–12. 1 indexed citations

Crew, Katherine D., Jillian L. Capodice, Heather Greenlee, et al.. (2011). Randomized, Blinded, Sham-controlled Trial of Acupuncture for the Management of Aromatase Inhibitor-associated Joint Symptoms in Women with Early-stage Breast Cancer.. Deutsche Zeitschrift für Akupunktur. 54(1). 40–41. 6 indexed citations

Reimers, Laura, Dawn L. Hershman, Matthew Maurer, et al.. (2011). Abstract A48: Pitfalls of using breast magnetic resonance imaging (MRI) in an early-phase breast cancer chemoprevention trial of vitamin D among high-risk postmenopausal women. Cancer Prevention Research. 4(10_Supplement). A48–A48. 1 indexed citations

Hershman, Dawn L., Louis H. Weimer, Antai Wang, et al.. (2010). Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Research and Treatment. 125(3). 767–774. 198 indexed citations

Kalinsky, Kevin, et al.. (2010). Abstract P1-07-01: Safety of High-Dose Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer. Cancer Research. 70(24_Supplement). P1–7. 2 indexed citations

10.

Crew, Katherine D., Jillian L. Capodice, Heather Greenlee, et al.. (2010). Randomized, Blinded, Sham-Controlled Trial of Acupuncture for the Management of Aromatase Inhibitor–Associated Joint Symptoms in Women With Early-Stage Breast Cancer. Journal of Clinical Oncology. 28(7). 1154–1160. 201 indexed citations

11.

Hershman, Dawn L., Don McMahon, Katherine D. Crew, et al.. (2009). Evaluation of the protective effects of zoledronic acid on bone mass in premenopausal women undergoing adjuvant chemotherapy following treatment discontinuation. Journal of Clinical Oncology. 27(15_suppl). 562–562. 1 indexed citations

12.

Crew, Katherine D., Jillian L. Capodice, Heather Greenlee, et al.. (2009). Randomized, blinded, placebo-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. Journal of Clinical Oncology. 27(15_suppl). 571–571. 3 indexed citations

13.

Crew, Katherine D., Anna J. Podolanczuk, Lois Brafman, Danielle Awad, & Dawn L. Hershman. (2009). Prospective Evaluation of Joint Symptoms in Postmenopausal Women Initiating Aromatase Inhibitors for Early Stage Breast Cancer.. Cancer Research. 69(24_Supplement). 5044–5044. 3 indexed citations

14.

Hershman, Dawn L., Donald J. McMahon, Katherine D. Crew, et al.. (2009). Prevention of Bone Loss by Zoledronic Acid in Premenopausal Women Undergoing Adjuvant Chemotherapy Persist up to One Year following Discontinuing Treatment. The Journal of Clinical Endocrinology & Metabolism. 95(2). 559–566. 43 indexed citations

15.

Zauderer, Marjorie G., et al.. (2008). Prospective evaluation of neurotoxicity in breast cancer patients treated with adjuvant paclitaxel. Journal of Clinical Oncology. 26(15_suppl). 20567–20567. 1 indexed citations

16.

Hershman, Dawn L., Donald J. McMahon, Katherine D. Crew, et al.. (2008). Zoledronic Acid Prevents Bone Loss in Premenopausal Women Undergoing Adjuvant Chemotherapy for Early-Stage Breast Cancer. Journal of Clinical Oncology. 26(29). 4739–4745. 127 indexed citations

17.

Crew, Katherine D., Heather Greenlee, Jillian L. Capodice, et al.. (2007). Prevalence of Joint Symptoms in Postmenopausal Women Taking Aromatase Inhibitors for Early-Stage Breast Cancer. Journal of Clinical Oncology. 25(25). 3877–3883. 368 indexed citations

18.

Tiersten, Amy, et al.. (2004). Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. Gynecologic Oncology. 92(2). 635–638. 50 indexed citations

19.

Modiano, Manuel, et al.. (2004). A phase II trial of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP) in patients with metastatic breast cancer. Journal of Clinical Oncology. 22(14_suppl). 864–864. 4 indexed citations

20.

Tiersten, Amy, Susan Talbot, Linda T. Vahdat, et al.. (2003). A Phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma. Cancer. 97(3). 537–544. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact